Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in the company's Ordinary Shares, filed pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by nine senior executives and directors on February 11, 2014, executed through the Company's ShareReward Plan. The transactions occurred at a price of 1631.63 pence per share. The acquisitions consisted of:
- Personal Contribution Element: 8 shares for most executives; 7 shares for Mr. P C Thomson and Dr. P J T Vallance.
- Matching Element (Company Contribution): 8 shares for most executives; 7 shares for Mr. P C Thomson and Dr. P J T Vallance.
Executives involved include Sir Andrew Witty, Mr. S Dingemans, Mr. S M Bicknell, Mr. R G Connor, Mr. D S Redfern, Ms. C Thomas, Mr. P C Thomson, Dr. P J T Vallance, Ms. E Walmsley, and Mrs. V A Whyte.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions described above.
Investor Verification Checklist
- Verify the total number of shares acquired by each named executive under both the personal and matching elements of the ShareReward Plan.
- Confirm the transaction price of 1631.63 pence per share against market data for February 11, 2014.
- Review the company's full ShareReward Plan rules to understand the vesting schedule and conditions attached to these acquisitions.
- Check subsequent filings for any changes in the total shareholdings of these directors following this transaction.